Tinengotinib

替恩戈替尼

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameTinengotinib
Drug Alias NameTT-00420TT 00420TT00420
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-A inhibitorsSerine/threonine-protein kinase Aurora-B inhibitorsVascular endothelial growth factor receptor antagonists +[7] 
TargetsSerine/threonine-protein kinase Aurora-ASerine/threonine-protein kinase Aurora-BVascular endothelial growth factor receptor +[7] 
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesTaiwan +[14] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesTransThera Sciences (Nanjing) Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAkeso Pharmaceuticals IncThe Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical SchoolTransThera Sciences (Nanjing) Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[16] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG